MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
January 3, 2005
Nathan Slaughter
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. mark for My Articles similar articles
The Motley Fool
September 29, 2010
Andrew Bond
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters. mark for My Articles similar articles
The Motley Fool
June 28, 2005
Mike Cianciolo
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. mark for My Articles similar articles
The Motley Fool
September 26, 2006
Ryan Fuhrmann
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? mark for My Articles similar articles
The Motley Fool
June 26, 2007
Ryan Fuhrmann
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down. mark for My Articles similar articles
The Motley Fool
January 7, 2010
Gerard Torres
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. mark for My Articles similar articles
The Motley Fool
July 6, 2007
Timothy M. Otte
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... mark for My Articles similar articles
The Motley Fool
August 15, 2005
Bobby Shethia
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. mark for My Articles similar articles
The Motley Fool
September 28, 2007
Timothy M. Otte
Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth. mark for My Articles similar articles
The Motley Fool
March 28, 2005
Alyce Lomax
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? mark for My Articles similar articles
The Motley Fool
January 3, 2006
Stephen D. Simpson
Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures. mark for My Articles similar articles
The Motley Fool
June 21, 2004
Seth Jayson
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore. mark for My Articles similar articles
The Motley Fool
April 9, 2007
Mike Cianciolo
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 4, 2008
Timothy M. Otte
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. mark for My Articles similar articles
The Motley Fool
September 21, 2006
Nathan Parmelee
Wal-Mart Goes Generic The supposed most terrible retailer of all is doing a very good thing with generic drug sales. The program will, of course, benefit Wal-Mart by creating additional traffic to its stores. This move could change the game for a number of retailers over the next few years. mark for My Articles similar articles
The Motley Fool
September 21, 2006
Vitaliy Katsenelson
Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them. mark for My Articles similar articles
The Motley Fool
September 27, 2004
Phil Wohl
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. mark for My Articles similar articles
The Motley Fool
March 23, 2011
Andrew Bond
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. mark for My Articles similar articles
The Motley Fool
September 27, 2005
Nathan Slaughter
All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors. mark for My Articles similar articles
The Motley Fool
September 22, 2006
Ryan Fuhrmann
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. mark for My Articles similar articles
The Motley Fool
December 21, 2007
Timothy M. Otte
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales. mark for My Articles similar articles
The Motley Fool
October 8, 2011
Shubh Datta
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. mark for My Articles similar articles
The Motley Fool
March 26, 2007
Ryan Fuhrmann
Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note. mark for My Articles similar articles
The Motley Fool
December 6, 2007
Selena Maranjian
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. mark for My Articles similar articles
The Motley Fool
August 15, 2007
Mary Dalrymple
Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money. mark for My Articles similar articles
The Motley Fool
September 27, 2007
Ryan Fuhrmann
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired. mark for My Articles similar articles
The Motley Fool
January 5, 2004
Jeff Hwang
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. mark for My Articles similar articles
The Motley Fool
January 12, 2010
Dayana Yochim
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. mark for My Articles similar articles
The Motley Fool
October 5, 2007
Timothy M. Otte
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition. mark for My Articles similar articles
The Motley Fool
July 6, 2004
Alyce Lomax
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. mark for My Articles similar articles
The Motley Fool
September 14, 2006
Ryan Fuhrmann
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. mark for My Articles similar articles
The Motley Fool
October 4, 2005
Seth Jayson
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. mark for My Articles similar articles
The Motley Fool
April 4, 2007
Timothy M. Otte
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies. mark for My Articles similar articles
The Motley Fool
June 22, 2006
Stephen D. Simpson
Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors. mark for My Articles similar articles
The Motley Fool
October 6, 2010
Rich Smith
This Just In: Upgrades and Downgrades Jefferies on Walgreen: Take two shares and thank me in the morning. mark for My Articles similar articles
The Motley Fool
October 7, 2010
DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio. mark for My Articles similar articles
The Motley Fool
March 22, 2004
Alyce Lomax
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. mark for My Articles similar articles
The Motley Fool
September 27, 2006
Michael P. Cecil
A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales. mark for My Articles similar articles
The Motley Fool
March 22, 2010
Dave Mock
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. mark for My Articles similar articles
The Motley Fool
March 24, 2011
Rick Aristotle Munarriz
It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak. mark for My Articles similar articles
The Motley Fool
August 1, 2006
Selena Maranjian
Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms. mark for My Articles similar articles
The Motley Fool
March 24, 2008
Timothy M. Otte
Expecting More From Walgreen The drugstore giant has managed to beat analyst estimates two quarters in a row, but earnings are lagging sales growth, and growth is slowing too. mark for My Articles similar articles
The Motley Fool
June 11, 2007
Mike Cianciolo
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. mark for My Articles similar articles
The Motley Fool
November 8, 2006
Michael P. Cecil
CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm. mark for My Articles similar articles
The Motley Fool
January 4, 2005
Seth Jayson
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. mark for My Articles similar articles
The Motley Fool
March 26, 2010
Cathy Applefeld Olson
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup. mark for My Articles similar articles
The Motley Fool
December 26, 2006
Matthew Crews
Walgreen Represents This drugstore business has proven itself; does its stock match up? mark for My Articles similar articles
The Motley Fool
November 2, 2006
Ryan Fuhrmann
CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 13, 2009
Dayana Yochim
Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions. mark for My Articles similar articles
The Motley Fool
April 11, 2008
Ryan Fuhrmann
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd. mark for My Articles similar articles